SpyGlass To Boost Ophthalmic Drug Adherence With Intraocular Delivery Platform

After $90m Series C

 
• By Ayisha Sharma

Emerging Company Profile: The US biotech SpyGlass is gearing up for a Phase I/II trial in glaucoma after recently closing a $90m fundraising to help advance its intraocular delivery platform to address poor treatment adherence in chronic eye diseases.  

Emerging Company Profile: SpyGlass Pharma
SpyGlass' Drug-Eluting Pads Are Attached To The Haptics Of The Lens • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs